Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HMS5552 in Patients With Type 2 Diabetes
NCT ID: NCT02077452
Last Updated: 2017-11-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
53 participants
INTERVENTIONAL
2014-03-31
2014-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary objective is to characterize the safety and tolerability of HMS5552 following multiple ascending doses in patients with type 2 diabetes mellitus after BID dosing for 8 days.
The secondary objectives include:
1. To determine the single dose and steady state pharmacokinetics of HMS5552 in patients with type 2 diabetes
2. To evaluate the single dose and steady state pharmacodynamics of HMS5552 in patients with type 2 diabetes
3. To further explore food-effect on HMS5552 pharmacokinetics and pharmacodynamics
A maximum total of 80 patients (10 in each dose group and assuming a maximum of 5\~8 dose levels). There will be 8 active and 2 placebo patients in each dose group. The safety, tolerability, pharmacokinetics and pharmacodynamics data after each dose cohort will be reviewed in blinded fashion before escalation to the next dose cohort.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HMS5552 dose 1
HMS5552 25\~400mg. Oral administration, twice per day.
HMS5552
Placebo
HMS5552 dose 2
HMS5552 25\~400mg. Oral administration, twice per day.
HMS5552
Placebo
HMS5552 dose 3
HMS5552 25\~400mg. Oral administration, twice per day.
HMS5552
Placebo
HMS5552 dose 4
HMS5552 25\~400mg. Oral administration, once per day.
HMS5552
Placebo
HMS5552 dose 5
HMS5552 25\~400mg. Oral administration, twice per day.
HMS5552
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HMS5552
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age: 18 to 65 years
* BMI: 20 to 29 kg/m2
* Mentally, physically and legally eligible to give informed consent.
* Willingness to adhere to the protocol requirement.
Exclusion Criteria
* Episodes of hypoglycemia
* Unstable cardiovascular diseases
* Hepatic diseases
* Kidney disease
* Mental or central nervous system diseases
* Clinical abnormal findings in ECG, labs and physical exams
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hua Medicine Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dalong ZHU, MD
Role: PRINCIPAL_INVESTIGATOR
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HMM0102
Identifier Type: -
Identifier Source: org_study_id